SGLT2 inhibitors: cardiorenal metabolic drugs for the ages
(Source: Journal of Clinical Investigation)
Source: Journal of Clinical Investigation - March 1, 2024 Category: Biomedical Science Authors: Ralph A. DeFronzo Source Type: research
Diabetes, SGLT-2 Inhibitors, and Urinary Tract Infection: a Review
AbstractPurpose of ReviewThe aim of this review is to focus on epidemiology, pathogenesis, risk factors, management, and complications of UTI in people with diabetes as well as reviewing the association of SGLT-2 inhibitors with genitourinary infections.Recent FindingsIndividuals diagnosed with T2DM are more prone to experiencing UTIs and recurrent UTIs compared to individuals without T2DM. T2DM is associated with an increased risk of any genitourinary infections (GUI), urinary tract infections (UTIs), and genital infections (GIs) across all age categories. SGLT2 inhibitors are a relatively new class of anti-hyperglycemic ...
Source: Current Diabetes Reports - March 1, 2024 Category: Endocrinology Source Type: research
IDF23-0318 SGLT2 inhibitors influence miRNAs in heart tissue of T2DM-induced rats
(Source: Diabetes Research and Clinical Practice)
Source: Diabetes Research and Clinical Practice - March 1, 2024 Category: Endocrinology Authors: H. Kiyak-kirmaci, A.N. Hazar-Yavuz, H.K. Elcioglu Tags: Cardiovascular Disease Source Type: research
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Trends Endocrinol Metab. 2024 Feb 29:S1043-2760(24)00032-8. doi: 10.1016/j.tem.2024.02.003. Online ahead of print.ABSTRACTInflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-in...
Source: Trends in Endocrinology and Metabolism: TEM - February 29, 2024 Category: Endocrinology Authors: Mona Mashayekhi Bilgunay Ilkin Safa Matthew S C Gonzalez Sangwon F Kim Justin B Echouffo-Tcheugui Source Type: research
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors
Trends Endocrinol Metab. 2024 Feb 29:S1043-2760(24)00032-8. doi: 10.1016/j.tem.2024.02.003. Online ahead of print.ABSTRACTInflammation plays an essential role and is a common feature in the pathogenesis of many chronic diseases. The exact mechanisms through which sodium-glucose cotransporter-2 (SGLT2) inhibitors achieve their much-acclaimed clinical benefits largely remain unknown. In this review, we detail the systemic and tissue- or organ-specific anti-inflammatory effects of SGLT2 inhibitors using evidence from animal and human studies. We discuss the potential pathways through which SGLT2 inhibitors exert their anti-in...
Source: Trends in Endocrinology and Metabolism: TEM - February 29, 2024 Category: Endocrinology Authors: Mona Mashayekhi Bilgunay Ilkin Safa Matthew S C Gonzalez Sangwon F Kim Justin B Echouffo-Tcheugui Source Type: research
Sodium Glucose Co-Transporter 2 Inhibitors and the Cardiovascular System: Current Knowledge and Future Expectations
Heart Int. 2023 Dec 1;17(2):12-18. doi: 10.17925/HI.2023.17.2.12. eCollection 2023.ABSTRACTDiabetic cardiomyopathy is a well-recognized clinical entity and reflects a complex relationship between metabolic substrates and myocardial function. Sodium glucose co-transporter 2 (SGLT2) inhibitors are antidiabetic agents that are found to exert multiple cardioprotective effects. Large clinical trials showed their beneficial effects on patients with heart failure, reducing the rates of rehospitalizations and improving kidney function. The aim of this review is to summarize the latest evidence in the literature regarding the multi...
Source: Heart International - February 29, 2024 Category: Cardiology Authors: Ioannis Boutsikos Eleftherios Beltsios Bastian Schmack Ioannis Pantazopoulos Dimitrios G Chatzis Source Type: research
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2... (Source: Cardiovascular Diabetology)
Source: Cardiovascular Diabetology - February 29, 2024 Category: Cardiology Authors: Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nystr öm, Thomas Klein, Gesine Paul, Cesare Patrone and Vladimer Darsalia Tags: Research Source Type: research
Expanding the Impact of SGLT2 Inhibitors in Chronic Kidney Disease
Am J Nephrol. 2024 Feb 28:1-4. doi: 10.1159/000536540. Online ahead of print.NO ABSTRACTPMID:38417403 | DOI:10.1159/000536540 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - February 28, 2024 Category: Urology & Nephrology Authors: Alaa T Makawi Yahya M K Tawfik Dave L Dixon Gearoid M McMahon Leo F Buckley Source Type: research
